Janus Henderson Group’s Adicet Bio ACET Stock Holding History

Janus Henderson Group’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-665	Closed	-$61.2K	–	2592
2023 Q1	$61.2K	Buy	+665	New	+$83.5K	﹤0.01%	2650

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Janus Henderson Group's ACET Position: Q2 2023 in Review

Janus Henderson Group sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 665 shares — an estimated $61.2K sold.

Janus Henderson Group first reported a position in ACET in Q1 2023 and held it in 1 quarter. The position peaked at $61.2K in Q1 2023. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

Janus Henderson Group reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
Janus Henderson Group sold 665 Adicet Bio shares in Q2 2023, an estimated $61.2K.
Janus Henderson Group first reported a position in Adicet Bio in Q1 2023 and held it in 1 quarter.
Janus Henderson Group's Adicet Bio position peaked at $61.2K in Q1 2023.
94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.